About the IBC

IBC "at a glance" Brochure

The IBC is the NIH required review board for all research involving recombinant or synthetic nucleic acid molecules.  View the brochure.

Brief History of the IBC:

The Institutional Biosafety Committee (IBC) was first registered with the USG in June 1991.  A decade later, the IBC was organizationally placed under the Research Conduct and Compliance Office (RCCO), and the committee was provided admistrative support with the establishment of the IBC Office. Currently two full-time personnel staff the IBC Office to provide support for the committee and research community.

The IBC is charged with the following responsibilities:

  • Review of ALL research proposals involving recombinant or synthetic nucleic acid molecules
  • Notifying the Principal Investigator of the outcome of review and committee recommendation(s)
  • Determination of reducing ("Downgrade Request")or increasing the biosafety containment levels (BSL)
  • Conducting periodic reviews ensuring compliance with the NIH Guidelines
  • Approving emergency plans covering accidental spills and/or personnel contamination developed and recommended by University Biosafety Officer(s) and the Department of Environmental Health and Safety
  • Reporting significant problems or violations of the NIH Guidelines to the appropriate federal agencies
  • The IBC may not authorize research experiments involving recombinant or synthetic nucleic acid molecules that are not covered by the NIH Guidelines until the NIH establishes the standard of containment
  • Performance of other functions as deemed necessary
Page updated 12 January 2017